A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis
De Soyza Anthony, Pavord Ian, Elborn J. Stuart, Smith David, Wray Heather, Puu Margareta, Larsson Bengt, Stockley Robert
Source: Eur Respir J 2015; 46: 1021-1032
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
De Soyza Anthony, Pavord Ian, Elborn J. Stuart, Smith David, Wray Heather, Puu Margareta, Larsson Bengt, Stockley Robert. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J 2015; 46: 1021-1032
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
LATE-BREAKING ABSTRACT: A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma Source: Annual Congress 2009 - Novel approaches in asthma Year: 2009
Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008
Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011
A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006
The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study Source: Eur Respir J, 54 (1) 1900439; 10.1183/13993003.00439-2019 Year: 2019
STRIDE-2 trial: a placebo-controlled study for sitaxsentan in PAH Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005
Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
Umeclidinium in patients with COPD: a randomised, placebo-controlled study Source: Eur Respir J 2014; 43: 72-81 Year: 2004
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study Source: Eur Respir J, 58 (5) 2004240; 10.1183/13993003.04240-2020 Year: 2021
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial Source: Eur Respir J, 51 (1) 1701926; 10.1183/13993003.01926-2017 Year: 2018
A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis Source: Eur Respir J 2014; 43: 1114-1123 Year: 2014
Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009
Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021 Year: 2022
Preventive effect of carbocysteine on exacerbation of asthma, GAIA randomised, placebo-controlled multi-centre study Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012